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Despite advanced understanding of the biology of atherosclerosis, coronary heart disease remains the leading cause of death worldwide.
Progress has been challenging as half of the individuals who suffer sudden cardiac death do not experience premonitory symptoms.
Furthermore, it is well-recognized that also a plaque that does not cause a haemodynamically significant stenosis can trigger a sudden car-
diac event, yet the majority of ruptured or eroded plaques remain clinically silent. In the past 30 years since the term ‘vulnerable plaque’
was introduced, there have been major advances in the understanding of plaque pathogenesis and pathophysiology, shifting from pursuing
features of ‘vulnerability’ of a specific lesion to the more comprehensive goal of identifying patient ‘cardiovascular vulnerability’. It has
been also recognized that aside a thin-capped, lipid-rich plaque associated with plaque rupture, acute coronary syndromes (ACS) are also
caused by plaque erosion underlying between 25% and 60% of ACS nowadays, by calcified nodule or by functional coronary alterations.
While there have been advances in preventive strategies and in pharmacotherapy, with improved agents to reduce cholesterol, throm-
bosis, and inflammation, events continue to occur in patients receiving optimal medical treatment. Although at present the positive pre-
dictive value of imaging precursors of the culprit plaques remains too low for clinical relevance, improving coronary plaque imaging may
be instrumental in guiding pharmacotherapy intensity and could facilitate optimal allocation of novel, more aggressive, and costly treatment
strategies. Recent technical and diagnostic advances justify continuation of interdisciplinary research efforts to improve cardiovascular
prognosis by both systemic and ‘local’ diagnostics and therapies. The present state-of-the-art document aims to present and critically ap-
praise the latest evidence, developments, and future perspectives in detection, prevention, and treatment of ‘high-risk’ plaques occurring
in ‘vulnerable’ patients.
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In the 1980s, Muller et al. studied coronary events triggered by morn-
ing awakening, anger, heavy exertion, and other stressors. The obser-
vation that a potential stressful trigger could be harmless on one day,
yet lead to a cardiac event sometime later led to the concept of the
‘vulnerable plaque’, initially defined in 19891 as a plaque at increased
risk of thrombosis (Supplementary material online, Table S1). Over
the past three decades, the focus on ‘vulnerable plaque’1,2
(Supplementary material online, Figure S1) has evolved into a broader
‘vulnerable patient and plaque’ concept,3,4 as the current evidence
suggests that clinically silent plaque ruptures may occur5 and that the
coexistence of ‘vulnerable plaques’ in a ‘vulnerable patient’—includ-
ing the prothrombotic milieu of circulating blood—is likely needed to
generate acute coronary events (Take home figure) (Supplementary
material online, Appendix—Evolution of the concepts of ‘vulnerable
plaque’ and ‘vulnerable patient’). It has been also recognized that
aside a thin-capped, lipid-rich plaque associated with culprit plaque
rupture, acute coronary syndromes (ACS) are also caused by plaque
erosion underlying between 25% and 60% of ACS nowadays,4,6 by
calcified nodule or by functional coronary alterations.
Some small-to-moderate sample size longitudinal imaging studies
have suggested that atherosclerotic plaques of differing maturity fre-
quently co-exist and their morphology may change over time, being
able to both gain and lose the features of vulnerability8–14; even up to
three quarters of vulnerable plaques might evolve towards a more
stable phenotype while on a high-intensity statin therapy.13
At present, the clinical consequences of detecting the features of
plaque vulnerability remain limited as the positive predictive value of
current imaging modalities for the prediction of major adverse car-
diac events (MACE) is too low for clinical relevance. However, such
limitations have prompted a number of technical advances including
both diagnostics and analytics. In 2003, Patrick W. Serruys, Antonio
Colombo, and Christodoulos Stefanadis founded an annual inter-
national meeting of medical scientists studying the detection and
treatment of vulnerable plaques and patients2; the expert discussions
that have occurred over the course of the past 15 years form the
basis for this state-of-the-art document aiming to present and critical-
ly appraise the latest evidence, developments, and future perspec-
tives in detection, prevention, and treatment of high-risk plaques
occurring in ‘vulnerable’ patients.
Imaging of the high-risk/culprit
coronary plaque
The search for the precursors of culprit plaque underlying acute car-
diac events has been the subject of multiple investigations using differ-
ent invasive and non-invasive imaging modalities.
Non-invasive imaging offers the potential as a screening tool to
identify plaques with features of vulnerability, indicating patients at
increased cardiovascular risk.15 Advanced computational modelling
allows the use of increasing amount of radiographic data (radio-
mics)16 in clinical risk estimation, i.e. a new machine learning-based
coronary computed tomography angiography (CCTA)-derived
profiling of adverse fibrotic and microvascular perivascular adipose
tissue remodelling has improved cardiac risk prediction using CCTA
over and above the current state-of-the-art17 (Figure 1). The advan-
ces in non-invasive coronary imaging, including CCTA, magnetic res-
onance angiography, and positron emission tomography (Figure 2),
have been recently reviewed in detail elsewhere.15
There are three intracoronary imaging modalities that have been
tested for their ability to identify high-risk plaques and to evaluate cul-
prit lesions: intravascular ultrasound (IVUS), intravascular optical co-
herence tomography (OCT), and near-infrared spectroscopy (NIRS)
(Figure 3). They have also been utilized to identify a response to
pharmacotherapy (Supplementary material online, Table S2).
With IVUS, a large plaque burden, small lumen area, and positive
remodelling have been demonstrated as strong markers of plaque
‘vulnerability’.22 Attenuated plaque or a necrotic core (especially
with a non-detectable fibrous cap, <150 lm thick according to the
resolution of the technique) by IVUS-virtual histology are also a sign
of a plaque vulnerability.23,24 However, IVUS has only limited ability
to identify the amount and distribution of lipid present in a plaque.
NIRS, which has been combined with IVUS in a multimodal catheter,
is quantitatively validated for the detection and characterization of
lipid content of a plaque. The relatively low spatial resolution of IVUS
limits its ability to assess the thickness of a fibrous cap over a lipid
core; OCT, which has an 10-fold higher resolution, is superior for
the detection of potentially vulnerable thin caps and remains the
most reliable imaging modality to confirm plaque erosion. Finally,
IVUS has no chemical sensitivity, which means that image contrast for
inflammation or biological instability is absent. These may potentially
be detected by local or systemic biomarkers, or molecular imaging.25
Near-infrared spectroscopy measures the lipid core burden based
on the differential absorbance and scattering of NIR light at different
wavelengths for different types of tissue. Several trials have demon-
strated the value of NIRS in predicting MACE (Figure 3).26–28
Recently, the Lipid-Rich Plaque Study in 1562 patients demonstrated
that non-flow-limiting plaques, which did not undergo percutaneous
coronary intervention (PCI) but were shown to be lipid-rich by
• As the majority of plaque ruptures or erosions are clinically si-
lent, it is likely that coexistence of ‘high-risk plaques’ within ‘vul-
nerable patients’ is required to generate a clinical event/acute
coronary syndrome.
• Plaque rupture, plaque erosion, calcified nodule, and functional
coronary alterations represent pathophysiological mechanisms
underlying ACS.
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NIRS, were associated with increased MACE at both the patient and
the plaque level 24months following PCI of an index lesion.29
It should be noted, however, that the events triggered by occlusive
thrombosis occurring over plaques without superficial lipid escape
the accurate prediction with NIRS, a consideration particularly essen-
tial in the context of the increasing recognition of the role of plaque
erosion as the cause of ACS.6 Currently, the PROSPECT II
(ClinicalTrial.org Identifier: NCT02171065) and PREVENT
(ClinicalTrial.org Identifier: NCT02316886) trials are underway, aim-
ing to further define the value of NIRS-IVUS in prediction of coronary
events; these studies are also evaluating the ability of IVUS, OCT, and
NIRS to guide localized treatment (stenting) of plaques identified by
imaging as having a high risk of becoming a future culprit lesion.
At present, the clinical consequences of detecting the ‘high-risk’
plaque features remain limited given that the positive predictive value
of available invasive imaging modalities for the prediction of adverse
events is too low for clinical relevance. However, such limitations
have prompted a number of further technical advances.
Algorithms, using the gold standard of plaque burden determined
by IVUS, are under development to improve the detection of plaque
burden by OCT.30 Recent developments in IVUS and OCT, including
higher resolution IVUS systems operating at 60MHz,
electrocardiography-gated, and Heartbeat OCT, provide a higher
longitudinal sampling rate without artefact due to cardiac motion
(Supplementary material online, Appendix—Developments in intra-
vascular imaging).
Hybrid intravascular imaging catheter-based systems have recently
been introduced to allow simultaneous acquisition of data by differ-
ent modalities with complementary strengths31 (Supplementary ma-
terial online, Appendix—Hybrid intravascular imaging catheters).
The combined OCT-NIRS, IVUS-OCT/OFDI hybrid catheter sys-
tems, plus other novel approaches using near-infrared fluorescence
(NIRF) molecular imaging, intravascular photoacoustics (IVPA), time-
resolved fluorescence spectroscopy, and fluorescence lifetime imag-
ing systems currently under development are summarized in Figure 4.
Molecular imaging with NIRF measures inflammation using a
ProSense marker and detects indocyanine green-illuminated plaque
endothelial barrier function impairment.25 Hybrid intracoronary
NIRF-OCT and NIRF-IVUS catheters, anticipated by 2020, may have
a value in improving risk stratification in patients with established cor-
onary artery disease (CAD).25 Fluorescence lifetime imaging, based
on measurement of the fluorescence emission decay time after mole-
cules have been excited with pulsed light. It can reportedly identify
compositional characteristics of superficial plaque.32 Intravascular
photoacoustics, a natural extension of IVUS that adds depth-resolved
tissue to the IVUS images, relies on the analysis of the sound pro-
duced by the thermal expansion of tissues after irradiation with
pulsed light. The photoacoustic response of each plaque depends on
the absorption characteristics of its components, which permits IVPA
to provide information about plaque composition. A study in an ath-
erosclerotic animal model is ongoing.33
Can the assessment of local
haemodynamic forces improve the
identification of vulnerable plaques and
patients?
Although the anatomic and chemical features of potentially vulner-
able plaques have been extensively studied, the majority of these
high-risk plaques remain quiescent and do not cause MACE.24,29,34,35
The low positive predictive value of current plaque characterization
methods indicates that additional information is needed to identify
vulnerable plaques in a manner that has clinical utility. There is
increasing evidence that haemodynamic-associated biomechanical
forces increase plaque vulnerability and may lead to destabilization
Take home figure High-risk and culprit plaques in ‘vulnerable patients’. The combination of ‘vulnerable patient’ phenotype and ‘high-risk pla-
que’ is likely required to produce an adverse cardiac event. Plaque rupture, plaque erosion, calcified nodule and functional coronary alterations repre-
sent pathophysiological mechanisms underlying acute coronary syndromes. Photography adapted from Partida et al.6 and Gijsen et al.7 (Creative
Commons Licence CC-BY-NC).
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Figure 1 Coronary computed tomography angiography in cardiovascular risk prediction. (A) Coronary computed tomography angiography-
adapted Leaman score. (B) Perivascular fat attenuation index. 95% CI, 95% confidence interval; HR, hazard ratio. Adapted from Mushtaq et al.18 and
Oikonomou et al.19
Figure 2 Schematic summary of advances in non-invasive imaging of coronary plaque. CCTA, coronary computed tomography angiography; FFR,
fractional flow reserve; 18F-FDG, 18F-fluorodeoxyglucose; 18F-NaF, 18F-sodium fluoride; MRA, magnetic resonance angiography; PET, positron emis-
sion tomography; USPIO, ultrasmall superparamagnetic iron oxide. Photography adapted from Joshi et al.20 and Chiribiri et al.21
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Figure 3 Intravascular imaging modalities in studies on high-risk plaques and vulnerable patients. CA, calcium; ESS, endothelial shear stress; IVUS,
intravascular ultrasound; LCBI, lipid core burden index; MACE, major adverse cardiac events; MLA, minimum lumen area; NA, not available; NIRS,
near-infrared spectroscopy; OCT, optical coherence tomography; PB, plaque burden; TCFA, thin-cap fibroatheroma; VH, virtual histology.
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..causing a clinical event.35–38 The most extensively studied biomech-
anical forces are endothelial shear stress (ESS), plaque structural
stress, and axial plaque stress.7,35,39,40 In addition, a fluid–structure
interaction model is being developed to define pulsatility as a deter-
minant of the risk of plaque rupture (Supplementary material online,
Appendix—Impact of local haemodynamic forces on plaque biology).
Although larger clinical studies and more data are required, initial
reports suggest that inclusion of biomechanical indices in prediction
models may increase the accuracy of predicting risk of plaque ero-
sion41,42—a pathophysiological mechanism recognized as underlying
a substantial proportion of acute coronary events.6
Prediction of plaque progression and vulnerability improves when
high plaque burden coexists with areas of both low and high wall
shear stress.35 The presence of low wall shear stress was associated
with the development of non-culprit MACE in the post hoc computa-
tional fluid dynamics (CFD) analysis of patients enrolled in the
PROSPECT study: baseline wall shear stress in patients with non-
culprit plaques leading to MACE was lower than in patients who did
not develop MACE during a median of 3.4 years of follow-up.36 It has
been also shown that high wall shear stress in the upstream part of a
plaque may contribute to the prognostic value of fractional flow re-
serve to predict myocardial infarction.37
Although CFD is a powerful research tool, such analysis requires
numerous assumptions and procedures, including three-dimensional
reconstruction of the vessel, meshing, and solving the Navier–Stokes
equation. The principles of appropriate ESS computation and its po-
tential clinical implications have been described in detail elsewhere.7
Prevention and treatment of
culprit plaques and vulnerable
patients
A systemic intervention with pharmacotherapy remains the key
intervention in prevention of developing culprit lesions in vulnerable
patients (Supplementary material online, Figure S2). The role of
Figure 4 Summary of potential advantages of hybrid catheters. FLIm, fluorescence lifetime imaging; IVPA, intravascular photoacoustics; IVUS, intra-
vascular ultrasound; NA, not available; NIRF, near-infrared fluorescence; NIRS, near-infrared spectroscopy; OCT, optical coherence tomography;
TRFS; time-resolved fluorescence spectroscopy.
• Non-invasive imaging offers the potential as a screening tool to
identify patients at increased cardiovascular risk, while invasive
imaging may further risk stratify patients who have presented
with symptomatic CAD.
• It is likely that plaque biomechanical forces act in a synergistic
manner with anatomic and biochemical vulnerable plaque fea-
tures to increase plaque vulnerability, promote destabilization,
and produce clinical events.
• New imaging modalities, multimodality catheters, and hybrid
approaches, in conjunction with CFD processing are under de-
velopment to improve the accuracy of predicting clinical events.
3002 M. Tomaniak et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article/41/31/2997/5836754 by Erasm
us U
niversiteit R
otterdam
 user on 09 Septem
ber 2020
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
aspirin in primary prevention—that has long been advocated to miti-
gate the prothrombotic milieu of circulating blood in case the culprit
lesion occurs—has been reappraised by three large randomized clin-
ical trials showing minimal benefits and consistent bleeding risks.43
Thus, beyond diet maintenance, exercise, and smoking cessation, ef-
fective hypolipidaemic regimens rather than prophylactic aspirin are
recommended for primary prevention.44
Improving coronary plaque imaging may be instrumental in guiding
pharmacotherapy—its intensity and duration—and could facilitate
optimal allocation of (such) novel, more ‘aggressive’, and costly treat-
ment strategies (i.e. new hypolipidaemic or anti-inflammatory agents).
While both pharmacological and mechanical intervention with PCI
are well established in management of ACS caused by culprit plaque
rupture, the concept of tailoring the treatment of ACS to its specific
underlying mechanism, as assessed by intravascular imaging, is gaining
an increasing interest. Specifically, the therapeutic approaches con-
centrating on antithrombotic agents rather than PCI in plaque ero-
sion have been suggested, given the reported differences in vascular
responses to PCI between plaque rupture and erosion, and the po-
tential benefits of avoiding the risk of stent thrombosis, restenosis,
and prolonged dual antiplatelet therapy.4,6
The single-centre EROSION study was the 1st proof-of-concept
investigation that demonstrated the feasibility and initial safety of
antithrombotic therapy without stenting in patients with OCT-
confirmed culprit plaque erosion, further supporting evaluation of
management schemes tailored to culprit plaquemorphology.45
Over and above statins, therapeutic approaches to reduce LDL-C
focused on a proprotein convertase subtilisin-kexin type 9 (PCSK 9)
as a therapeutic target—a serine protease targeting low-density lipo-
protein receptors for lysosomal degradation. Evolocumab and aliro-
cumab, two human monoclonal antibodies directed against PCSK 9,
administered on a background of statin therapy, have been shown to
markedly decrease LDL-C levels and significantly reduce cardiovascu-
lar risk.46 With accumulating data supporting the efficacy of newer
lipid-lowering agents in further reducing LDL-C,47 appropriate
patients selection, therapy duration, and cost-effectiveness are gain-
ing an increased interest. Although effective in stabilizing lipid-rich,
thin-capped precursors of culprit plaque rupture, lipid-lowering agent
might be less effective in preventing endothelial cell denudation and
subsequent plaque erosion, that has been shown to frequently occur
within lipid-poor regions of artery wall. A better understanding of the
mechanisms that underlie superficial erosion is required to propose a
more specific therapeutic approaches; innate immune activation of in-
timal endothelial cells (by engagement of the toll-like receptor 2),
neutrophils, and neutrophil extracellular traps appears to contribute
more prominently to thrombosis due to superficial erosion than in
case of plaque rupture, pointing towards inflammatory pathways as
promising new targets.48
Indeed, evidence of ongoing inflammatory processes in ruptured
or eroded culprit plaques has led to trials assessing anti-inflammatory
agents in the prevention of cardiovascular events.8,49
Canakinumab—a high-affinity fully human monoclonal anti-human
interleukin-1b (IL-1b) antibody—demonstrated a beneficial effect on
MACE in the CANTOS trial.46,50 Nevertheless, the translational
aspects of these findings still need to be further elucidated, with a
focus on individuals presenting high baseline inflammatory biomarker
concentrations, subjects responding with a pronounced reduction of
C-reactive protein or IL-6, and particular attention to side effects,
such as infections. While a 1st trial using methotrexate yielded a null
result,51 another anti-inflammatory compound—colchicine—has
reduced the rates of MACE after a myocardial infarction in the recent
COLCOT trial; further studies evaluating this compound are ongoing
(LoDoCo2, CLEAR-SYNERGY, CONVINCE).
It should be noted, however, that the trials evaluating novel anti-
inflammatory and lipid-lowering agents demonstrated a benefit of
15% reduction in mortality and adverse cardiovascular events, as
compared to their control groups; there was still 85% residual risk
of mortality and MACE that persisted despite these aggressive and in-
novative systemic therapies.46,50 If new local imaging and diagnostic
strategies (anatomic, biochemical, and biomechanical) were able to
identify the precursors of culprit plaques with greater prognostic dis-
crimination, future pre-emptive local strategies targeting the remain-
ing 85% risk could potentially provide incremental clinical benefit.
With the improvements in stent design and secondary prevention
drug therapy, PCI could recently reduce the risk of ‘hard’ clinical end-
points, including cardiovascular death or myocardial infarction, when
performed in non-culprit lesions causing severe stenoses (>_80% by
visual estimation or >_60% by quantitative coronary angiography).52 If
ongoing imaging and diagnostic efforts identify a truly high-risk fea-
tures in jeopardy of destabilization and MACE in a plaque with <80%
luminal obstruction, then pre-emptive strategies could be applied be-
yond the COMPLETE trial inclusion criteria,52 and potentially im-
prove clinical outcomes more substantially. Nevertheless, to date
there is no conclusive evidence demonstrating that sealing of high-
risk plaques that are not significantly stenotic is clinically safe and
improves prognosis.53
Conclusions and future
perspectives
Despite significant advances in diagnostics, ranging from blood testing
to genetics, imaging, haemodynamics, and ‘omics’, identification of
patients and plaques at higher risk of adverse events remains limited.
The positive predictive value of detecting the high-risk plaque charac-
teristics remains too low for clinical relevance, and it is also still un-
clear which individual plaque features are most useful in predicting
the ‘hard’ clinical endpoint of death and myocardial infarction.
• Atherosclerosis—as a systemic disease with focal manifesta-
tions—may require systemic pharmacologic therapy and local
interventional treatment of advanced lesions.
• Improving coronary plaque imaging may be instrumental in
guiding pharmacotherapy, facilitating optimal allocation of novel,
more aggressive, and costly treatment strategies and tailoring the
treatment of ACS to a specific underlying mechanism (culprit
plaque rupture, erosion, calcified nodule, or functional coronary
alterations).
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Nevertheless, improving imaging modalities supported by ongoing
deep machine learning-based developments provide new avenues of
precision medicine that are likely to translate into personalized pre-
ventive and therapeutic approaches to high-risk plaques occurring in
‘vulnerable’ patients. Further interdisciplinary research taking advan-
tage of opportunities offered by both systemic and ‘local’ diagnostics
and therapies is warranted.
Supplementary material
Supplementary material is available at European Heart Journal online.
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